Insulet Corporation
- Industrie
- Medical Devices
- Bourse
- États-Unis
- Pays / Région
- USA
- Date d'introduction en bourse
- 15 mai 2007
- Effectif
- 5 400
- Site web
- www.insulet.com
Fourchette de valorisation composite · prudent $110–$120 / raisonnable $120–$160 / optimiste $170–$190. À $145.76, Dans la fourchette de valeur intrinsèque raisonnable.
À la publication $144.94 (31 mai 2026)
Pas encore d'analyse sur cette valeur dans votre langue.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Données EODHD, présentées dans la devise de reporting ; à titre indicatif uniquement, ne constitue pas un conseil en investissement.
Historique
Bientôt disponibleCette section est en cours de complétion ; revenez bientôt.
Position dans le secteur
Bientôt disponibleCette section est en cours de complétion ; revenez bientôt.
